Betamethasone dipropionate/calcipotriol - MC2 Therapeutics

Drug Profile

Betamethasone dipropionate/calcipotriol - MC2 Therapeutics

Alternative Names: BDP/calcipotriene - MC2 Biotek; Calcipotriol/betamethasone dipropionate - MC2 Therapeutics; MC2 01; MC2-01 (calcipotriol + BDP); MC2-14; PADcombo; PADscalp

Latest Information Update: 02 May 2017

Price : $50

At a glance

  • Originator Drug Delivery Solutions ApS
  • Developer MC2 Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Plaque psoriasis
  • Discontinued Psoriasis

Most Recent Events

  • 02 May 2017 Discontinued MC2-14 (PADscalp) for Scalp psoriasis in Germany (Topical)
  • 02 May 2017 Phase-II/III clinical trials of MC2-01 (PADcombo) in Plaque psoriasis in Germany (Topical) (MC2 Therapeutics pipeline, May 2017)
  • 03 Apr 2017 MC2 Biotek changed its name to MC2 Therapeutics and Drug Delivery Solutions (a subsidiary of MC2 Biotek) does not exist
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top